Released: February 9, 2024
Department of Defense
Congressionally Directed Medical Research Programs (CDMRP)
Prostate Cancer Research Program
Anticipated Funding Opportunities for Fiscal Year 2024 (FY24)
The FY24 Defense Appropriations Bill has not been signed into law. Although FY24 funds have not been appropriated for the Prostate Cancer Research Program (PCRP), the PCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY24 funding opportunities. This pre-announcement should not be construed as an obligation by the government.
The FY24 Defense Appropriations Act is anticipated to provide funding for the PCRP to support innovative, high-impact prostate cancer research. The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).
The PCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY24 funding opportunities. This pre-announcement should not be construed as an obligation by the government. The FY24 PCRP funding opportunity announcements for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the announcements are released.
The mission of the FY24 PCRP is to fund research that will eliminate death and suffering from prostate cancer and enhance the well-being of Service Members, Veterans, and all the patients, Families, and caregivers who are experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care; therefore, applications are required to address one or more of the following FY24 PCRP Overarching Challenges:
- Improve quality of life to enhance outcomes and overall health and wellness for those impacted by prostate cancer Applications should aim to understand the impact of prostate cancer on the quality of life of the cancer survivor, their Family, their caregivers, and their community with the goal of improving and enhancing quality of life and overall health and wellness. Studies should consider both short- and long-term quality of life outcomes. Areas of particular interest include:
- The mental and emotional health of patients and their Families/caregivers
- Impact of quality-of-life considerations on decision-making after diagnosis and/or treatment
- Identification of vulnerable groups of patients and their Families at great risk of quality-of-life detriments
- Implementation of factors or interventions that improve access to evidence-based care, quality-of-life outcomes, and overall health and wellness
- Develop new treatments or improve upon existing therapies to improve outcomes for patients with lethal prostate cancer Applications must be directly related to prostate cancer with a high risk of death, including high-risk localized disease, regional disease, and/or metastatic prostate cancer.
- Advance health equity and reduce disparities in prostate cancer Applications must be directly relevant to better understanding and/or reduction of inequities and disparities that impact a person, their Family, or their caregiver's ability to prevent, detect, manage, and survive prostate cancer.
- Define the biology of prostate cancer progression to lethal prostate cancer to reduce death Applications must be directly related to high-risk, very high-risk, and metastatic prostate cancer. The FY24 PCRP also strongly encourages research involving patient derived materials or specimens related to ongoing or completed clinical trials. Refer to the National Comprehensive Cancer Network guidelines for risk assessment definitions (https://www.nccn.org/patients/guidelines/content/PDF/prostate-advanced-patient.pdf).
Treatments may address any stage in the continuum of care, including local therapies such as surgery or radiation designed to treat patients with a high risk of death from the disease. Proposed treatments are highly encouraged to consider preserving patient quality of life and not focus only on survival outcomes.
Applications should not focus on active surveillance, low-risk and intermediate-risk prostate cancer, and/or biochemical recurrence. Refer to the National Comprehensive Cancer Network guidelines for risk assessment definitions (https://www.nccn.org/patients/guidelines/content/PDF/prostate-advanced-patient.pdf).
Inequities may arise from socioeconomic status, race or ethnicity, geography, environment, lifestyle, sexual and/or gender identification, access to care (in rural or urban settings), or other factors.
Health inequities may include physical, mental, or emotional health differences, as well as social and financial differences experienced primarily in high-risk or underserved prostate cancer patients.
Implementation of factors or interventions that improve access to evidence-based care, quality-of-life outcomes, and overall health and wellness.
High-risk populations include, but are not limited to, people of African descent (including Caribbean), genetically predisposed populations, Service Members, and Veterans. Underserved populations include, but are not limited to, men with limited access to clinical care and resources (in rural or urban settings) and sexual and/or gender minorities.
|Key Mechanism Elements
|Data Science Award
|Independent investigators at all levels
|Early Investigator Research Award
By March 31, 2025,
|Exploration – Hypothesis Development Award
Updated for FY24!
|Investigators at or above the level of postdoctoral fellow (or equivalent)
|Idea Development Award
Independent investigators at all levels
Investigators that meet the following criteria at the application submission deadline date:
|Implementation Science Award
NEW for FY24!
Independent investigators at all levels
|Physician Research Award
At the time of application submission, the PI must be either:
A pre-application is required and must be submitted through the Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final funding opportunity announcements that will be available for downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using Assistance Listing Number (ALN, formerly CFDA) 12.420.
Submission deadlines are not available until the funding opportunity announcements are released. For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage. For more information about the PCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.health.mil).
Point of Contact:
CDMRP Public Affairs
Last updated Friday, February 9, 2024